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Mitochondrial NLRX1 is a member of the family of
nucleotide-binding domain and leucine-rich-repeat-
containing proteins (NLRs) that mediate host innate
immunity as intracellular surveillance sensors against
common molecular patterns of invading pathogens.
NLRX1 functions in antiviral immunity, but themolec-
ular mechanism of its ligand-induced activation
is largely unknown. The crystal structure of the
C-terminal fragment (residues 629–975) of human
NLRX1 (cNLRX1) at 2.65 A˚ resolution reveals that
cNLRX1 consists of an N-terminal helical (LRRNT)
domain, central leucine-rich repeat modules (LRRM),
and a C-terminal three-helix bundle (LRRCT).
cNLRX1 assembles into a compact hexameric archi-
tecture that is stabilized by intersubunit and interdo-
main interactions of LRRNT and LRRCT in the trimer
and dimer components of the hexamer, respectively.
Furthermore, we find that cNLRX1 interacts directly
with RNA and supports a role for NLRX1 in recogni-
tion of intracellular viral RNA in antiviral immunity.
INTRODUCTION
Innate immunity provides the first line of host defense against
invading microorganisms and subsequently stimulates adaptive
immunity. Such an immediate response relies upon germline-en-
coded pattern recognition receptors (PRRs), including Toll-like
receptors (TLRs), nucleotide-binding domain and leucine-rich-
repeat-containing proteins (NLRs), and RIG-1-like receptors
(RLRs), which recognize pathogen-associated molecular
patterns (PAMPs), such as bacterial lipopolysaccharide,
flagellin, and viral RNA (Akira et al., 2006; Beutler et al., 2007;
Medzhitov, 2007). NLRs function as intracellular surveillance
sensors against microbial products and danger signals and
thereby trigger host defense pathways via activation of the
NF-kBpathway and inflammatory caspases (Inohara and Nun˜ez,
2003). After discovery of the first NLR member, NOD1 (Inohara
et al., 1999), the number of NLR family members has grown
rapidly (34 in mice, 23 in humans) (Ting and Davis, 2005).Although NLR members share low primary sequence identities
(10%–25%) (Proell et al., 2008), most exhibit a characteristic
multidomain structure consisting of an N-terminal effector
domain (ED; caspase activation and recruitment domain
[CARD] or pyrin), a central nucleotide-binding and oligomeriza-
tion domain (NOD; NACTH or NOD-NAD), and a C-terminal puta-
tive ligand-binding and regulatory leucine-rich repeat (LRR)
domain (Harton et al., 2002). Recently, the NLR family has gained
more attention, because polymorphisms or mutations in certain
NLR genes (NOD1, NOD2, NLRP1, and NLRP3) and dysregula-
tion of their products are associated with inflammatory disor-
ders, such as Blau syndrome, Crohn’s disease, or early-onset
sarcoidosis (Dieude´ et al., 2011; Lu et al., 2010; Molnar et al.,
2007; Pontillo et al., 2011; Rosenstiel et al., 2007).
Among NLRs, NLRX1 (also known as NOD9) is unique in that it
localizes to the mitochondria through an N-terminal mitochon-
drial targeting (MT) sequence (Arnoult et al., 2009; Moore et al.,
2008; Tattoli et al., 2008). Like other NLR proteins, NLRX1 is
a proinflammatory activator that stimulates the production of
reactive oxygen species (ROS) via TNF-a activation (Arnoult
et al., 2009; Tattoli et al., 2008). Moreover, NLRX1 can also
downregulate inflammatory responses as a negative regulator
of RIG-1 and TLRs through interaction with the mitochondrial
antiviral signaling adaptor (MAVS) and TRAF6-IKK, respectively
(Allen et al., 2011; Moore et al., 2008; Xia et al., 2011). Such find-
ings have extended our knowledge of the function of NLRs from
that of a simple immune activator to a more complex immune
modulator. As another example, NLRC5 regulates both nega-
tively in NF-kB and type-1 interferon responses (Cui et al.,
2010) and positively in inflammasome activation (Davis et al.,
2011). Thus, NLRs participate in diverse biological processes
in innate immunity.
With such diverse biological outcomes, numerous efforts have
been made to understand the molecular mechanism whereby
NLR is activated. Collective analyses of NLR members and
homologous proteins have led to proposals that ligand-induced
activation of NLR is accompanied by conformational changes
from a closed and inactive monomeric or dimeric form to an
active, higher oligomeric complex through self- and hetero-olig-
omerization via NOD and ED domains, respectively (Faustin
et al., 2007; Franchi et al., 2009; Riedl et al., 2005). Nevertheless,
it has been debated whether NLRs recognize ligands directly or
indirectly in the first step of the signaling process. In previousImmunity 36, 337–347, March 23, 2012 ª2012 Elsevier Inc. 337
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the cognate ligand recognition site was mapped onto the LRR
domain (Girardin et al., 2005; Inohara et al., 2005; Moore et al.,
2008; Tanabe et al., 2004). However, these data do not exclude
an indirect sensing of PAMPs through an accessorymolecule, as
postulated that ligand recognition of NLRP3 was assisted by
thioredoxin-interacting protein (TXNIP) (Zhou et al., 2010).
Here, we present the crystal structure of the C-terminal frag-
ment of human NLRX1 (cNLRX1) at 2.65 A˚ resolution. The
cNLRX1 structure reveals a three-domain architecture consist-
ing of an N-terminal helical domain, a central LRR motif, and a
C-terminal three-helix bundle. Consistent with gel filtration and
analytical ultracentrifugation analyses, cNLRX1 forms a hexamer
through trimerization of dimers in the crystal via extensive inter-
domain and intersubunit interactions. Moreover, we show that a
direct interaction of the C-terminal fragment of NLRX1 with RNA
ligands plays a key role in NLRX1-mediated reactive oxygen
species (ROS) activation. Finally, cNLRX1 displays a series of
positively charged electrostatic patches on the surface that
may correspond to a nucleic acid binding site on NLRX1.
RESULTS
Oligomerization of cNLRX1
The C-terminal fragment of human NLRX1 (residues 629–975,
hereafter referred to as cNLRX1) (Figure 1A) was expressed in
a baculovirus expression system and purified to homogeneity.
Size exclusion chromatography analysis revealed that the puri-
fied recombinant cNLRX1 protein eluted in two major peaks
corresponding to a monomer (apparent MW, 39 kDa) and
a hexamer (apparent MW, 240 kDa) (Figure S1A available on-
line). A minor peak was also observed between the two major
peaks in a concentration-dependent manner and probably
represents dimer formation. In addition, the hexameric form
dominates at higher concentrations and upon longer storage of
the purified cNLRX1. Such monomer, dimer, and hexamer forms
were similarly found by analytical ultracentrifugation (AUC) anal-
ysis (Figure S1B). Thus, we conclude that cNLRX1 can adopt
multiple forms from monomer to dimer to hexamer in solution.
Overall Structure
To gain insight into the atomic details of the LRR domain struc-
ture in NLR proteins, we determined the crystal structure of
cNLRX1 by the multiple anomalous wavelength dispersion
(MAD) method (Hendrickson, 1991) with a potassium tetranitro
platinum (II) (K2(NO2)4Pt) derivative crystal. The crystal structure
of cNLRX1 was refined to 2.65 A˚ (Table 1) and the final structure
contains residues 667–970 out of the expressed protein residues
629–975 (Figure S2).
The crystal structure reveals that the cNLRX1 monomer is
composed of three distinct domains: an N-terminal helical do-
main (LRRNT, residues 667–696), a central LRR-module domain
(LRRM, residues 697–901), and a C-terminal three-helix bundle
(LRRCT, residues 906–970) (Figures 1A, 1B, and S2). The LRRNT
domain contains two a helices (Na1, residues 672–686; Na2,
688–696) that are oriented at 120 via a kink at Asn687, and
Na2 directly connects to the LRRM domain. The central LRR
domain folds into a typical crescent shape and consists of eight
LRR motifs with their canonical, parallel b strands disposed on338 Immunity 36, 337–347, March 23, 2012 ª2012 Elsevier Inc.the concave side. This concave face of the LRRM domain encir-
cles one side of the LRRCT domain, which consists of three anti-
parallel a helices (Ca1, residues 906–923; Ca2, 926–945; Ca3,
950–970) (Figure 1B).
As observed in solution, the cNLRX1 crystal structure assem-
bles into a hexamer via 2-fold crystallographic symmetry (Fig-
ure 1C, left) and 3-fold noncrystallographic symmetry (NCS)
axes (Figures 1C, right, and S1C). In the crystal, the cNLRX1
dimer buries 1,550 A˚2 of accessible surface area (ASA) (corre-
sponding to 9.9% of the monomer surface) with the LRRCT
domains at center of the dimer. In an asymmetric unit (ASU),
three cNLRX1 subunits (subunits A, B, and C) come together
as an NCS trimer in the shape of a three-petal pinwheel.
The trimer is formed with three LRRNT domains positioned
around the 3-fold NCS axis, which function as a pin holding
the three protruding petals composed of the LRRM and LRRCT
domains (Figure 1C, right). Approximately 2,054 A˚2 of ASA is
buried upon trimerization, which corresponds to 13.5% of the
surface of each monomer. As a result, the LRRCT-mediated
dimerization and LRRNT-centered trimerization assemble six
cNLRX1 modules into a relatively compact hexameric structure
(100 A˚3 105 A˚3 80 A˚), which is more precisely a trimer of three
dimers with approximate dihedral D32 symmetry.
Structure overlay of three cNLRX1 monomers (A, B, and C)
shows that the LRRNT and LRRM domains are almost identical
between subunits with an rmsd of 0.1 A˚, whereas the LRRCT
domains display greater structure displacement (Figure S1D).
We consider that those observed structure differences are a
result of crystal packing (Figure S1E) and do not affect the
description and interpretation of the NLRX1 structure. Hereafter,
the cNLRX1 structure of subunit A (cNLRX1A) is mostly
described unless otherwise specified.
LRRM Domain
A DALI database search reveals that the overall fold of cNLRX1
LRRM domain resembles those of other LRR-containing
proteins (Figure 2A; Kobe, 2001). The closest structural homo-
logs of cNLRX1 LRRM are from segments of ribonuclease
inhibitor (RI) (Kobe and Deisenhofer, 1996) and RAN GTPase
activating protein 1 (RANGAP1) (Hillig et al., 1999). Although
cNLRX1 LRRM can be superimposed on RI and RANGAP1,
cNLRX1 LRRM nevertheless deviates substantially from RI and
RANGAP1 both in primary sequence (sequence identity, 23%
and 19%, respectively) and in tertiary structure (rmsds, of 2.5 A˚
for 195 Ca atoms and 2.4 A˚ for 188 Ca atoms, respectively).
Each motif of LRR1–LRR7 consists of a single b strand on the
concave side, an a helix on the convex side, and two connecting
loops, forming a typical b strand-ascending loop-a helix-
descending loop structure, similar to RI LRRs (Kobe and
Deisenhofer, 1993). However, the last LRR motif, LRR8, does
not contain an a helix and proceeds directly to LRRCT domain.
LRR2 is also aberrantly short with only 25 residues, unlike the
other LRR motifs (LRR1 and LRR3–LRR7) that are either 28 or
29 residues long (Figure S2). In other LRR structures, the pres-
ence of an irregular length LRR motif in consecutive LRRs often
causes a distortion in LRR curvature or a formation of a protrud-
ing loop or a groove on the surface of LRR structure. In the
cNLRX1 LRR structure, the short LRR2 introduces a groove at
Arg751 (position 1 of LRR3), which is a connecting residue
Figure 1. Overall Structure of cNLRX1
(A) Schematic representation of NLRX1 (MT-NOD-NAD-LRR) and the cNLRX1 construct (LRRNT [Na1 and Na2; blue]-LRRM [LRR1-8; magenta]-LRRCT [Ca1-3;
red]) that was used for structural and ligand binding studies. Residue numbers corresponding to the domain boundaries and the N- and C-terminal ends that are
ordered in the crystal structure are indicated.
(B) A cNLRX1monomer (subunit A) is rainbow colored from blue (N terminus) to red (C terminus) in a ribbon diagram. Secondary structural elements of b strands,
a helices, and loops are indicated as arrows, helical ribbons, and extended coil structures, respectively.
(C) cNLRX1 hexamer. The cNLRX1 hexamer is formed by trimerization of dimers through dihedral D32 symmetry. The crystallographic 2-fold symmetry is
highlighted by a side view of the cNLRX1 hexamer and the 2-fold symmetry axis between subunit A and A0 is visualized as an oval (left). The 3-fold non-
crystallographic symmetry is shown in the top view of the hexamer and its axis is represented by a triangle at the trimer center (right). The cNLRX1 trimer is shown
in ribbons (subunit A [LRRNT, blue; LRRM, magenta; LRRCT, red]; subunit B, cyan; subunit C, yellow) and transparent surface representation (subunit A, gray;
subunit B, cyan; subunit C, yellow), and its 2-fold symmetry-related partners (subunits A0, B0, C0) are in a green surface representation. Labels for the various
domain interfaces are boxed with arrows and a prime (0) is used to label an intersubunit contact partner. LRRM residues and descriptions are labeled in italics. A
subunit (or residue) that is related by 2-fold symmetry to the other (reference) subunit (or residue) in a dimer is distinguished by underline. These same colors,
symbols, and fonts are used in the rest of figures.
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Structure and Functional Analysis of NLRX1between theLRR2ahelix and the LRR3b strand. TheArg751 side
chain points toward LRR1 and is deeply inserted below Ser722
and Gly723 of the protruding LRR1-LRR2 loop (Figure 2B). The
Arg751 guanidinium group is extensively coordinated through
hydrogen bonds or polar contacts to five carbonyl oxygen atoms
from the main chain of the surrounding Leu698, Leu720, Ser722,
Gly723, and His725 residues. In addition, Leu727 provides a
hydrophobic stacking interaction below Arg751 to sandwich
Arg751 between the LRR2-LRR3 loop and Leu727.
cNLRX1 LRR Modules
Primary sequence and tertiary structure comparisons of indi-
vidual cNLRX1 LRR motifs confirm that they contain the ex-pected conserved residues of the LRR consensus motif
(xL2xxL5xL7xxN10xL12xxxxL17xxL20xxxL24) as seen in other
LRR structures (Figure S2; Kobe and Kajava, 2001). Positions
2, 5, 7, 12, 17, 20, and 24 are occupied by apolar residues,
such as leucine, isoleucine, valine, and phenylalanine, which
construct the hydrophobic core of the LRR structure. Position
10 selectively places the buried polar residues (asparagine or
threonine) in a location that stabilizes the ascending loop
between a b strand and an a helix via hydrogen bonds with
neighboring main-chain atoms of the loop.
In cNLRX1, the N-terminal end of the LRRM hydrophobic core
is protected by the adjacent LRRNT domain (e.g., LRRMC by
LRRNTA, as described below, i.e., LRRNT-LRRM0 contact) fromImmunity 36, 337–347, March 23, 2012 ª2012 Elsevier Inc. 339
Table 1. Crystallographic Data and Refinement Statistics of
cNLRX1 Structure
K2(NO2)4Pt Derivative
Peak Inflection Remote
Data Collection
Space group C2221
Cell parameters (A˚) a = 99.01
b = 123.47
c = 145.85
Resolution (A˚) 20.00–2.65
Highest resolution (A˚) 2.79–2.65
Wavelength (A˚) 1.0719 1.0716 0.8550
No. observations 194,003 193,637 219,316
No. unique reflections 25,742 25,749 26,342
Rmerge (%)
a 6.0 (28.2)b 3.1 (30.0)b 7.0 (59.0)b
I/sigma 6.9 (2.7)b 7.4 (2.3)b 6.8 (1.3)b
Completeness (%) 97.9 (87.7)b 97.9 (87.2)b 100.0 (100.0)b
Multiplicity 7.5 (4.7)b 7.5 (4.7)b 8.3 (8.7)b
Phasing
Resolution (A˚) 15.00–3.00
Pt sites (SOLVE) 4
Overall figure of merit 0.58
Refinement
Resolution (A˚) 20.00–2.65
No. reflections (total) 24,448
No. reflections (test) 1,311
Rcryst (%)
c 22.3
Rfree (%)
d 26.7
Average B value (A˚2) 79.0
No. protein atoms 6,657
No. water molecules 8
No. ligand atoms 4 (Pt)
Rmsd bonds (A˚) 0.016
Rmsd angles () 1.56
Ramachandrane (favored) 97.0%
Ramachandrane (outliers) 0.4%
aRmerge= ShklSij Ii(hkl)  <I(hkl)> j / ShklSi Ii(hkl).
bNumbers in parentheses were calculated from data from the highest
resolution shell.
cRcryst = Sj jFobsjjFcalcj j / SjFobsjwhere Fcalc and Fobs are the calculated
and observed structure factor amplitudes, respectively.
dRfree = as for Rcryst, but for 5% of the total reflections chosen at random
and omitted from refinement.
eCalculated with MolProbity (http://molprobity.biochem.duke.edu).
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Structure and Functional Analysis of NLRX1exposure to solvent (Figure 3A). The amphipathic Na1 helix
places its apolar residues Pro672, Leu675, Leu676, Leu679,
Phe680, and Tyr683 near LRR1 and buries 560 A˚2 of ASA.
Furthermore, amore distal LRRNT residue, Gln668A, intercalates
between the N-terminal region of subunit A (residues
669A672A) and the LRR1-b strand of subunit C (LRR1-bC), and
its side-chain nitrogen and oxygen atoms form hydrogen
bonds with the main-chain oxygen of Leu670A and the amide
nitrogen of Asn702C, respectively. At the C-terminal end of340 Immunity 36, 337–347, March 23, 2012 ª2012 Elsevier Inc.cNLRX1 LRRM, four arginine residues (Arg857 and Arg860 of
LRR6 and Arg880 and Arg884 of LRR7) are found on the surface,
resulting in a burial of 470 A˚2 of ASA (Figure 3B). Although the
nonpolar carbon atoms of the arginines make van der Waals
interactions with the hydrophobic residues of LRR6 and LRR7,
their polar guanidinium groups are disposed on the cNLRX1
surface. In addition, the C-terminal end of the LRRM domain
(LRR8) is further stabilized by the 2-fold symmetry-related
LRRCT domain in the cNLRX1 dimer (see below).
Numerous Interdomain Contacts in the
cNLRX1 Structure
Three domains, LRRNT, LRRM, and LRRCT, mutually interact
with each other, generating various interdomain interfaces to
stabilize the monomer structure and enable formation of multiple
oligomers, such as dimer, trimer, and hexamer. First, an interdo-
main contact between the LRRM and LRRCT domains (LRRM-
LRRCT) occurs in the cNLRX1 monomer, where the LRRCT
domain diagonally buttresses the concave face of the LRRM
structure, burying 630 A˚2 of ASA of the LRRM domain (Figures
1B and 3C). The LRRM-LRRCT interactions include 7 hydrogen
bonds, 1 salt bridge, and 25 van der Waals contacts composed
of residues between Ca1-Ca3 and the LRRM b strands
(Figure 3C).
Besides the intrasubunit interactions with the LRRM, the
LRRCT domain forms a parallel homodimeric interaction with
its 2-fold symmetry-related partner (i.e., LRRCTA-LRRCTA
0
,
LRRCTB-LRRCTC
0
, and LRRCTC-LRRCTB
0
) (Figure 1C, left).
The 2-fold assembly introduces two discrete symmetry contact
areas of LRRCT-LRRCT0 (Figure 4A) and LRRCT0-LRRM (Fig-
ure 4B). The LRRCT-LRRCT0 contact results in a burial of
530 A˚2 of ASA through symmetrical interactions between
Ca1 and Ca10 (Tyr909, Trp910, Val912, Ile913, Asn920, and
Trp924) (Figure 4A). At the LRRCT0-LRRM contact, Ca20 partially
covers the C-terminal end of cNLRX1 LRR7 and LRR8 with 10
hydrogen bonds, 42 van der Waals contacts, and 510 A˚2 of
ASA buried (Figure 4B). In particular, hydrogen bonds between
Ca20 (Asp9390, Ser9430, and Arg9520) and main chain of LRR8
(Ser899, Leu900, and Thr901) appear to stabilize the LRR8
b strand and loop. Thus, the LRRCT domain plays a key role in
cNLRX1 dimerization and provides structural support for the
cNLRX1 LRR modules through intrasubunit and intersubunit
interactions.
The cNLRX1 forms a trimer in the ASU of the crystal by 3-fold
noncrystallographic symmetry (Figure S1C). Three Na1 helices
from subunits A, B, and C are arranged in a triangle (Na1 triangle)
at the center of the cNLRX1 trimer. The Na1 triangle is sur-
rounded by Na2 and LRR1, generating LRRNT-LRRNT0 and
LRRNT-LRRM0 contacts among three subunits (Figures 1C,
right, and 4C). Around the 3-fold axis, three equivalent sets of
two phenylalanine residues, Phe681 and Phe685 from Na1,
form a six aromatic ring stack in a double-layered circle with
an average ring-to-ring distance of 4 A˚. At the intercept of
the Na1 triangle, these phenylalanine residuesmake intersubunit
p$$$Cb-Cg and p$$$Cg-Cd stacking interactions such that, for
example, Phe681A and Phe685A interact with the aliphatic moie-
ties of Glu684C and Gln688C, whose side chains hydrogen
bond with His678A and with Gln686A and Arg689C, respectively.
His678A and His682A, nearby the phenylalanines (Figure 4C),
Figure 2. Structure of cNLRX1 LRRM Domain
(A) Comparison of the cNLRX1 LRRM structure with other
LRR structures. Porcine RI (PDB ID code 1bnh; yellow)
and RANGAP1 (PDB ID code 1yrg; cyan) were super-
imposed onto cNLRX1 LRRM (magenta) by Ca atoms.
(B) Close-up view of the cNLRX1 LRR2 interactions. The
aberrantly short LRR2 introduces a groove in the loop
connecting LRR2 and LRR3 (LRR2-3 loop). Arg751 is
shown in a stick model with surface representation
(carbon, gray; nitrogen, blue) and its interacting residues
are represented by stick models (carbon, cyan; nitrogen,
blue; oxygen, red). Hydrogen bonds are depicted in black
dashed lines.
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through van der Waals interactions with Leu670C, Ala692C, and
Leu695C and hydrogen bonds with Gln688C and Ser691C.
Such LRRNT-LRRNT0 interactions are buttressed by other
NCS-related interdomain contacts between Na1A and the prox-
imal N-terminal surface of LRRC (LRRNT-LRRM0) (Figure 1C,
right). Therefore, we conclude that the LRRNT domains function
to stabilize the trimerization of three cNLRX1 dimers and the re-
sulting hexamer buries 20,210 A˚2 of ASA.
To address the role of cNLRX1 oligomerization in NLRX1 func-
tion, we introduced dimerization- or trimerization-disrupting
mutations by replacing interface residues with aspartate to
introduce an unfavorable negative charge into their correspond-
ing interfaces, which would thus disfavor oligomerization.
When mutant cNLRX1 constructs were expressed in a baculovi-
rus expression system, each mutant protein was found to
be severely aggregated and could not be biophysically charac-
terized. These mutations were then introduced into the full-
length NLRX1 construct for cellular ROS study. Compared to
the wild-type NLRX1, the mutant constructs substantially
decreased poly(I:C)-stimulated ROS production in HeLa cellsFigure 3. cNLRX1 LRRM Contacts
(A) Intersubunit LRRNT-LRRM0 interactions. Na1A (blue cartoon and gray sticks
structure).
(B) A series of arginine residues displayed on the C-terminal NLRX1 LRRM surface
residues (857, 860, 880, and 884) on the surface of the C-terminal LRR are depi
orange. Their neighboring hydrophobic LRR residues are also shown in a stick m
(C) Intrasubunit LRRCT-LRRMcontact. Two a helices of the LRRCT domain, Ca1 a
and main-chain atoms of residues involved in the LRRCT-LRRM contact are de
dashed lines. LRRM domain is shown in surface representation.(Figure S3). These results suggest that NLRX1 dimerization and
trimerization are both probably conserved in the full-length
protein and should be maintained to provide NLRX1 stability
and cellular function.
Specific RNA Interaction of cNLRX1
Taking advantage of known NLRX1 function in antiviral
responses against viral RNA (Tattoli et al., 2008), we tested
whether the RNA ligand binding site is located in the C-terminal
region of NLRX1. We performed native polyacrylamide gel elec-
trophoresis (native PAGE) analysis (Figure S4). The presence of
poly(I:C) and single-stranded RNA (ssRNA) resulted in a mobility
change of the purified cNLRX1 protein, whereas none of the
double-stranded (ds) and ssDNAs shifted the position of the
cNLRX1 bands. In order to assess binding affinity between
the purified cNLRX1 and various RNA ligands, we monitored
polarization shifts of 50-fluorescein-labeled ssRNAs and dsRNAs
in 16- and 21-mers, as well as a 46-mer F-ssRNA (ssRNA-46),
upon cNLRX1 binding. All ssRNA and dsRNA ligands bound
to cNLRX1 and their binding affinities were estimated to be
1–1.6 mM of Kd for ssRNAs and 0.1–0.2 mM of Kd for dsRNA) provides an N-cap to cover the hydrophobic residues from LRR1C (yellow
. The NLRX1 LRRM is shown in ribbon and surface representation. Four arginine
cted in ball-and-stick models (carbon, gray; nitrogen, blue) and highlighted in
odel.
nd Ca3, diagonally buttress the concave face of the LRRMdomain. Side-chain
picted in a ball-and-stick representation. Hydrogen bonds are shown in black
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Figure 4. Intersubunit Contacts for cNLRX1 Oligomerization
(A) In the cNLRX1 dimer, the LRRCT domain packs parallel to the 2-fold symmetry-related LRRCT (LRRCT-LRRCT0 interaction) and the view shown is
perpendicular to the 2-fold symmetry axis. Residues in Ca1-Ca10, which symmetrically interact with each other, are shown in a ball-and-stick representation on
their respective gray and green surfaces.
(B) LRRCT0-LRRM interactions in the cNLRX1 dimer. The C-terminal region of LRRM domain makes contacts with Ca20 residues and Ca30 Arg952 from its
dimerization partner. LRRM residues are shown in gray with surface representation and Ca20 residues and Arg9520 in green with cartoon display. Interface
residues are highlighted in a ball-and-stick model. Hydrogen bonds are displayed in dashed lines.
(C) LRRNT-LRRNT0 interactions in the cNLRX1 trimer. Intersubunit LRRNT-LRRNT0 interactions are formed at Na1 and N-terminal Na2 around the NCS 3-fold
axis. Subunit affiliation (A, B, and C) is designated by a superscript with a different color scheme (subunit A, black; B, blue; C, yellow). Hydrogen bonds and
stacking interactions are shown in black and green dashed lines, respectively. A network of hydrogen bonds is formed between the C-terminal region of Na1 and
the beginning of Na2, including pairs of Glu686 and Gln688 residues that connect from one subunit to the other. For clarity, only main-chain atoms are drawn
for Arg689.
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Structure and Functional Analysis of NLRX1ligands, indicating a 5- to 10-fold increase in binding affinity with
dsRNA ligands (Figure 5A). These observations suggest that
NLRX1 directly recognizes viral RNA for antiviral innate immunity
and that this interaction occurs through the C-terminal region of
NLRX1.
Potential RNA Binding Site on cNLRX1
With our cNLRX1 crystal structure, we further investigated
whether any discrete positive patch or residue was positioned
on the cNLRX1 surface that could accommodate negatively
charged RNA molecules. The surfaces of LRRM ascending
lateral side and LRRCT residues on the same plane are highly
negatively charged, thus implying that those residues are prob-
ably excluded from direct recognition of RNA ligands. On the
other hand, a series of continuous positive patches on the
cNLRX1 surface could be responsible for RNA binding (rectangle
in Figure 5B, left). A large continuous patch (patch A, magenta
ellipse in Figure 5B, right) is created by residues from the
LRR1–LRR3 descending lateral side (Arg699, Arg724, His725,
Arg753, and K754) and Arg689 of the LRRNT. In addition, three
positive LRRCT residues (Arg944, Lys953, and Arg964) and
C-terminal end of the LRRM domain (Arg857, Arg860, and
Arg895) form another patch (patch B, green in Figure 5B, right).
The patch B expands its surfacewith its symmetry-related equiv-
alent residues, and the resulting combined patch B-B0 is contin-
uous with patch A-A0 in the cNLRX1 hexamer (Figure 5B, left). To
support our prediction, a point mutation of Arg699 to a glutamate
(cNLRX1 R699E) on patch A ablated cellular ROS stimulation in
HeLa cells (Figure 5C) and substantially disrupted poly(I:C) inter-
action in native PAGE (Figure 5D). Indeed, Arg699 is presumed to
be present on the surface of full-length NLRX1 with a homology
model based on the Apaf-1 structure (PDB ID code 1z6t) (Fig-342 Immunity 36, 337–347, March 23, 2012 ª2012 Elsevier Inc.ure S5; Riedl et al., 2005). Therefore, we conclude that the posi-
tively charged arginine at residue 699 (patch A) on the cNLRX1 is
a putative RNA binding site, although other residues on positive
patch A or B could be involved in NLRX1-RNA ligand interaction.
DISCUSSION
Here, we have presented the crystal structure of the C-terminal
fragment of human NLRX1 protein (cNLRX1) and provided
evidence to support specific interaction of cNLRX1 with an
RNA ligand. The cNLRX1 exhibits a three-domain architecture
of an N-terminal a-helical domain (LRRNT), central LRRmodules
(LRRM), and C-terminal three-helix bundle (LRRCT). Extensive
interdomain and intersubunit interactions are observed and
result in the trimerization of three dimers that leads to formation
of a hexamer in the crystal. The cNLRX1 hexamer is also found in
solution by size exclusion chromatography and analytical ultra-
centrifugation analyses.
Our cNLRX1 structure includes LRRNT that consists of two
a helices (Na1 andNa2).While the LRRNT helices are intertwined
with each other, their associated interactions occur exclusively
between subunits (intersubunit interactions) and thereby deliver
stabilizing elements to the NLRX1 hexamer. Simultaneously, the
amphipathic Na1 helix of LRRNT protects the hydrophobic core
of the LRRM domain of the adjacent subunit in the trimer (e.g.,
LRRNTA for LRR1C) from exposure to solvent as an N-terminal
capping motif of LRR structure. Thus, NLRX1 is unique in that
N-terminal a helices provide intersubunit stabilization of the
N-terminal LRRM as well as mediate subsequent higher oligo-
merization. However, the well-characterized TLR family, another
innate immune receptor with LRRs, displays a disulfide-linked
b-hairpin that flanks the N-terminal LRRs to protect the LRR
Figure 5. cNLRX1-RNA Interaction
(A) Fluorescent polarization (FP) analysis with fluorescein-labeled ssRNA and dsRNA to determine binding affinities of cNLRX1 for RNA ligands. The y axis
indicates DFP, for which the FP value is normalized using that without cNLRX1.
(B) Electrostatic potential representation of the cNLRX1 structure. Electrostatic surface potentials of the cNLRX1 hexamer are shown in the same orientation as
Figure 1C and contoured from red (10kT/e) to blue (+10kT/e). A continuous positive surface is highlighted in cyan rectangle (left). Two positive patches, patch A
and B, are depicted in magenta and green ellipses, respectively (right), and expand to become a continuous basic surface via 2-fold crystal symmetry. Arg699 is
highlighted in turquoise circle.
(C) The critical role of patch A residue Arg699 in the cellular ROS response. Poly(I:C)-stimulated ROS production of NLRX1 mutants (R699E or R771E) in HeLa
cells was normalized to that of full-length wild-type NLRX1. Arg771 is located on the LRRM convex surface away from the proposed RNA binding sites (patches A
and B) and its mutant R771E was included as a control. As expected, NLRX1 R771E exhibited ROS production comparable to full-length, wild-type NLRX1. In
contrast, Arg699 belongs to putative RNA binding patch A (B, right) and its mutation to glutamate completely disrupted ROS production.
(D) Reduced RNA binding of cNLRX1 R699E compared towild-type cNLRX1 (cNLRX1WT). cNLRX1WT and itsmutant cNLRX1 R699E proteins were purified and
their RNA binding were monitored by native PAGE. The cNLRX1 R699E binding to RNA was decreased by at least 15- to 20-fold compared to that of
cNLRX1 WT.
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merization (Bella et al., 2008; Botos et al., 2011). An additional
NLRX1-specific feature is that Gln668A at the N terminus partic-
ipates in a hydrogen bond network of the b sheet structure to a
neighboring LRR motif by interacting with Asn702C-amide
nitrogen of LRR1bC. The critical role of the Gln668 in NLRX1
protein folding was underscored by the extreme instability of a
cNLRX1 variant (residues 669–975) that does not contain
Gln668. Although we obtained crystals of this truncated protein,
X-ray diffraction data were observed only to 6 A˚ resolution.
Taken together, LRRNT is indispensible for LRR structural integ-
rity through mutually dependent LRRNT-LRRNT0 and LRRNT-
LRRM0 interactions, resulting in NLRX1 oligomerization.
In general, NLRs are described as having a three-domain
organization of ED-NOD-LRR domains (Ting and Davis, 2005).Alternatively, a four-domain architecture of ED-NOD-NAD-
LRR can be designated, where NOD is subdivided into a
nucleotide binding NOD (a region with Walker A and B motifs
in a length of100 amino acids residues) and a NOD-associated
domain (NAD, 200–300 residues) (Albrecht and Takken, 2006;
Proell et al., 2008). In the conventional three-domain description,
the NADwas neglected because of very low sequence identity in
NLRs and because it does not contain any known sequence
motif. Recently, NAD region has been recognized as a putative
regulatory region that possesses 3–4 independent structure
motifs (Proell et al., 2008; Riedl et al., 2005). NAD domain muta-
tions in NOD1 and NOD2 resulted in constitutively active pheno-
types, but additional mutations in the first and second LRR
motifs downregulated the activity to a basal level (Tanabe
et al., 2004). Similar NAD regulatory regions have also beenImmunity 36, 337–347, March 23, 2012 ª2012 Elsevier Inc. 343
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Although LRRNT residues were recognized within the putative
LRR domain in an earlier primary sequence analysis of NLRX1
(Moore et al., 2008; Tattoli et al., 2008), our cNLRX1 structure
reveals that LRRNT domain is a separate structure unit distinct
from the LRRM domain. The contacts between LRRNT and
LRRM stabilize the LRR fold and simultaneously involve NLRX1
oligomerization. Given those observations, if we consider that
the LRRNT domain is a part of the C-terminal region of the
NAD domain, we can explain how such functional complementa-
tion between NAD-LRR residues in NOD1 and NOD2 could be
accomplished by direct NAD-LRR interaction.
The effector domains (ED; pyrin in NLRP proteins and CARD in
NOD proteins) of NLRs share common characteristic a-helical
structures and mediate homotypic ED-ED dimerization for
downstream signaling, but an ED has not been identified in
NLRX1 by primary sequence analysis (Moore et al., 2008; Tattoli
et al., 2008). Unexpectedly, our cNLRX1 structure contains
another structural motif (the LRRCT domain) at its C-terminal
end that diagonally buttresses the inner concave face of the
LRRmodules. The LRRCT exhibits an exclusively a-helical struc-
ture and mediates cNLRX1 dimerization via symmetric LRRCT-
LRRCT0 interactions, as EDs in other NLRs do. These features
allow us to propose that the LRRCT domain would correspond
to an effector domain in NLRX1. If so, NLRX1may adopt an atyp-
ical domain organization where the N-terminal MT sequences
are required for mitochondrial localization, the central NOD-
NAD-LRR domains for ligand recognition, and the C-terminal
ED for dimerization.
Upon activation, NLRs have been believed to self-oligomerize
through NOD domains and to heterodimerize via ED-ED interac-
tions. But interactions between the LRR and other domains have
been underappreciated. Our cNLRX1 structure reveals that its
canonical LRR motifs are unexpectedly flanked by the N- and
C-terminal a helices that appear to play an essential role in stabi-
lizing the LRR fold, as well as the overall oligomeric structure.
The contacts between LRRM and LRRCT of cNLRX1 resemble
heterodimeric interactions of LRR-containing receptor with
protein ligand, which is also mediated through LRR concave
side, for example, glycoprotein Iba with von Willebrand factor
A1 (Huizinga et al., 2002), ribonuclease inhibitor with ribonu-
clease A (Kobe and Deisenhofer, 1995), and mosquito LRR
protein LRIM1 with APL1C (Baxter et al., 2010). Furthermore,
mutation of the oligomerization interfaces in LRRNT and/or
LRRCT of cNLRX1 resulted in no expression of soluble protein.
Similar mutations of a full-length NLRX1 construct reduced
cellular ROS stimulation in mammalian cells. Thus, the LRRNT
and the LRRCT domains are important for protein stability by
mediating cNLRX1 trimerization and dimerization, respectively.
Such findings may provide a new insight, besides NOD-medi-
ated oligomerization, that NLRs can adopt the various dynamic
oligomerization states that should be required for the cellular
signaling cascade upon ligand recognition.
Since the first discovery of the NLR family (Inohara et al.,
1999), it has been hotly debated how NLR recognizes its ligands
because of a lack of direct evidence for NLR interaction with its
cognate ligands. It is noteworthy that there have been discrep-
ancies and differences in the assigned function of NLRX1, either
as antiviral response activator (Tattoli et al., 2008) or as a negative344 Immunity 36, 337–347, March 23, 2012 ª2012 Elsevier Inc.immune regulator of RIG-1 and TLRs (Allen et al., 2011; Moore
et al., 2008; Xia et al., 2011), and in its subcellular localizations,
either on the outer mitochondria membrane (Moore et al.,
2008) or inside the mitochondrial matrix (Arnoult et al., 2009),
thus requiring further clarification to decipher how NLRX1 could
engage in such various functions. Another recent finding is
that NLRX1 is also present to some extent in the cytoplasm
and that its association with the IKK complex varies on cellular
activation (Xia et al., 2011). Collectively, the different cellular
functions of NLRX1 could be attributable to differences in its
subcellular localizations or associated signaling molecules.
Despite these proposals of diverse functions, it is evident that
the NLRX1 activities are exerted in response to intracellular viral
RNA and poly(I:C) (Arnoult et al., 2009; Tattoli et al., 2008). Here
we demonstrate a direct physical interaction of purified cNLRX1
(residues 629–975) with poly(I:C), ssRNAs, and dsRNAs. Based
on electrostatic surface analysis of cNLRX1, we propose two
basic patches as potential RNA binding sites. Indeed, a patch
A residue, Arg699, plays a critical role in RNA binding and
cellular ROS response. Nevertheless, it is highly likely that the
NLRX1-RNA recognition would occur with more than a single
residue, as for TLR3 that uses its opposite ends, N- and
C-terminal sites, for the RNA binding (Liu et al., 2008). Therefore,
we conclude that C-terminal region of NLRX1 is indispensible not
only for RNA binding (Arg699) but also for oligomerization of the
full-length NLRX1 protein.
Finally, from the structure of a NLR distant homolog, apoptotic
protease activating factor 1 (Apaf-1), we propose a model for the
full-length NLRX1 hexamer. Our cNLRX1 structure lacks the
NOD and the N-terminal region of the NAD domains that are
present in the Apaf-1 structure. In the full-length NLRX1 model,
the NOD-NAD domains extend from the LRR domain and deco-
rate the exterior surface of the NLRX1 hexamer. The putative
RNA binding regions, patches A and B, are still exposed to
solvent and accessible to binding by RNA. Because the NOD
domain is also exposed in the full-length NLRX1 hexamer model,
the NOD domain would be available to self-oligomerize to a ring
structure as well as to directly interact with other interacting part-
ners, such as MAVS. To complete our understanding of the
NLRX1 activation mechanism, crystal structures of NLRX1 com-
plexed with its RNA ligand or with its interacting partners now
need to be elucidated.EXPERIMENTAL PROCEDURES
Expression and Purification of cNLRX1
Numerous NLR constructs were generated and tested in Escherichia coli,
Drosophila, and baculovirus expression systems to obtain soluble and homo-
geneous recombinant proteins for structural studies of NLR members. One
construct (669–975) that encodes a putative LRR domain of human NLRX1
provided sufficient soluble, homogeneous material for structural studies.
However, proteins from the initial construct were relatively unstable and aggre-
gated during purification. Crystals were obtained, but diffracted to only 6 A˚
resolution. The original construct was further modified to improve protein
stability and crystal packing for improved X-ray diffraction. The optimized
construct contains human NLRX1 residues 629 to 975 (cNLRX1). The cNLRX1
coding region was amplified by PCR with C-terminal Strep-Tactin II and His6
tags and ligated into a pAcGP67 baculovirus transfer vector (BD Biosciences).
Recombinant baculovirus of cNLRX1 was obtained by transfecting SF9 insect
cells with the cloned plasmid DNA and a linearized baculovirus DNA (AB
vector). cNLRX1 was expressed in Hi5 insect cells for 2 days with amplified
Immunity
Structure and Functional Analysis of NLRX1recombinant virus. The cells were harvested, resuspended in PBS, and lysed
with a high-pressure homogenizer (Avestin). Supernatant containing recombi-
nant cNLRX1 protein was cleared by centrifugation at 10,000 rpm followed by
filtration. cNLRX1 protein was purified by three-step column procedure with
Ni-NTA (QIAGEN), Strep-Tactin affinity (IBA), and gel filtration (GE Healthcare)
chromatography. The purified recombinant cNLRX1 protein was 99% pure
with a final yield of 0.9 mg per 10 l culture and its identity was confirmed
by tandem MS/MS (TSRI Center for Mass Spectrometry).
Crystallization and Data Collection
cNLRX1 was crystallized at 23C by sitting drop vapor diffusion. cNLRX1 crys-
tals were obtained by mixing 0.5 ml of protein solution (9 mg/ml) with 0.7 ml of
reservoir solution containing 18% PEG 1000 and 200 mM Tris (pH 8.0). Crys-
tals were soaked in 5 mM potassium tetranitroplatinate for experimental
phasing and cryo-protected in 35% PEG 1000 and 250 mM Tris (pH 8.0).
Native and platinum derivative X-ray diffraction data of cNLRX1were collected
at the Advanced Photon Source (APS) beamline 23ID-B and the Stanford
Synchrotron Radiation Lightsource (SSRL) beamline 11-1, respectively.
X-ray data were processed with MOSFLM (Leslie, 1992) and Scala (Evans,
1997). Data collection statistics are summarized in Table 1.
Structure Determination and Refinement
The cNLRX1 structure was determined by the MAD method (Table 1). With
intensity data from three wavelengths, four of heavy atom sites were located
by SOLVE (Terwilliger and Berendzen, 1999). After solvent flipping (27%
solvent content), as implemented in the crystallography and NMR system soft-
ware (CNS) (Bru¨nger et al., 1998), the map revealed clear density for a helices
and bulky side chains, which were used to define the register of the residues
with the amino acid sequence. The cNLRX1 structure was iteratively built by
COOT (Emsley and Cowtan, 2004) and refined by REFMAC5 with NCS
restraints and TLS corrections (Vagin et al., 2004). Because the data sets
collected from a platinum derivative crystal showed the best diffraction to
2.65 A˚ resolution, the final cNLRX1 structure was refined with the platinum
peak wavelength data. The native structure at 2.9 A˚ resolution was also solved
bymolecular replacement withMolRep (CCP4, 1994), with the refined cNLRX1
structure as a search model. An overlay of these structures resulted in an rmsd
of 0.1 A˚, underscoring their structural identity regardless of platinum derivati-
zation. Refinement statistics are summarized in Table 1. The model of cNLRX1
has excellent stereochemistry with just one outlier (Thr792 in the LRR4 loop,
but in good agreement with its corresponding electron density) in the Rama-
chandran plot calculated by MolProbity (http://molprobity.biochem.duke.
edu). Several regions were not built in the final model because of poor electron
density that include the N- and C-terminal regions (residues 629–666 and 971–
975), a LRR7-LRR8 loop (887–893), a connecting loop between the LRRM and
LRRCT domains (residues 902–905), and loops in LRRCTC (Figure S2). The
overall Wilson B factor was estimated to 74.5 A˚2, confirming that portions of
the cNLRX1 structure are relatively flexible. Five cysteines are present in
cNLRX1, but no disulfide bonds are observed, as expected for an intracellular
protein. The cNLRX1 structure includes four platinum sites and eight ordered
water molecules bound to cNLRX1 protein residues.
All figures were made with Pymol (DeLano, 2002) and electrostatic poten-
tials were calculated with APBS.
Measurement of Cellular ROS Production
Mammalian cell expression constructs of full-length NLRX1 (residues 1–975)
with a C-terminal Flag tag were generated by PCR and ligated into pcDNA3.1A
(Invitrogen). Mutagenesis was done by QuickChange site-directed mutagen-
esis kit (Stratagene). Cellular ROS measurement was carried out as described
previously (Tattoli et al., 2008). In brief, HeLa cells were transiently transfected
with NLRX1 expression constructs or a negative control, pcDNA3.1A with
FuGENE (Roche) for 18 hr. Subsequently, the transfected cells were stimulated
by poly(I:C) (Invivogen). Intracellular ROS accumulation was detected with the
fluorescent probe (CM-H2DCFDA; Invitrogen) at 3 hr after stimulation.
Fluorescence Polarization Analysis
Fluorescence polarization analysis (Lundblad et al., 1996) was applied to
measure the binding affinity of cNLRX1 for RNA ligands utilizing Tecan plate
reader (Tecan Group Ltd.). Binding was monitored as a function of theincreased polarization/anisotropy of fluoresceinated 16-, 21-, and 46-mer
RNAs (Oligosetc) when cNLRX1 was titrated into a 100 ml solution. Binding
assays were carried out in triplicate in 25 mM HEPES (pH 7.4), 150 mM
NaCl, and 1 mM b-mercaptoenthanol at 25C.ACCESSION NUMBERS
The atomic coordinates and structure factors for cNLRX1 (PDB ID code 3UN9)
have been deposited in the Protein Data Bank, Research Collaboratory for
Structural Bioinformatics, Rutgers University (http://www.rcsb.org).SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and can be found with this
article online at doi:10.1016/j.immuni.2011.12.018.
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